APLS - Apellis Sobi inks licensing pact for systemic pegcetacoplan

Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum (BIOVF) have collaborated to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy.Sobi will receive global co-development and exclusive ex-US commercialization rights for systemic pegcetacoplan, while Apellis retains U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, which is being developed by Apellis in two Phase 3 trials in geographic atrophy (also known as atrophic age-related macular degeneration).Sobi will make an upfront payment of $250M to Apellis and up to $915M in milestone payments, and will contribute $80M as reimbursements over a four-year period for R&D support the initial development plan. Both the parties have agreed to split costs 50/50 for any future global studies beyond the initial development plan.The companies will jointly advance systemic pegcetacoplan in five parallel registrational programs including two new hematological studies planned to start in 2021 (cold agglutinin disease, hematopoietic stem cell transplantation-associated thrombotic microangiopathy). These join ongoing programs

For further details see:

Apellis, Sobi inks licensing pact for systemic pegcetacoplan